Talazoparib
CAS No. : 1207456-01-6
(Synonyms: BMN-673; LT-673)
| Size | Price | Stock |
|---|---|---|
| 5mg | $70 | In-stock |
| 10mg | $100 | In-stock |
| 25mg | $180 | In-stock |
| 50mg | $250 | In-stock |
| 100mg | $400 | In-stock |
| 200mg | $550 | In-stock |
| 500 mg | Get quote | |
| 1 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-16106 |
| M.Wt: | 380.35 |
| Formula: | C19H14F2N6O |
| Purity: | >98 % |
| Solubility: | DMSO : 25 mg/mL (ultrasonic) |
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].
IC50 & Target:IC50: 0.57 nM (PARP1)[1]
Ki: 1.2/0.87 nM (PARP1/2)[1]
In Vitro: Talazoparib shows an EC50 of 2.51 nM in cellular PARylation assay[1].
Talazoparib shows EC50s of 0.3 nM, 5 nM and 0.31 for MX-1 cells (BRCA1 mutant), Capan-1 cells (BRCA2 mutant) and MRC-5 cells (normal)[1].
In Vivo: Talazoparib (0.33 mg/kg; i.g.; once daily; for 28 days) exhibits antitumor activity against BRCA1 mutant breast cancer model in mice[1].
Talazoparib exhibits moderate oral bioavailability (rat 56%) and Cmax (rat 7948 ng/mL) following oral administration (rat 10 mg/kg)[1].
Talazoparib exhibits the terminal elimination half-life (rat 2.25 h) due to plasma clearance (2 mL/min/kg) following intravenous administration (rat 5 mg/kg)[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Talazoparib
- Cat. No.:
- HY-16106
- Quantity:
Your information is safe with us.